Leucovorin as an Antidepressant Adjunct in Elderly Inpatients With Treatment-resistant Depression

Parnika Prashasti Saxena, MD^a ; Helen Kyomen, MD, MS^b,c,d

Prim Care Companion CNS Disord 2021;23(2):20m02767

ABSTRACT

Objective: To assess the safety and tolerability of folinic acid as an augmentation agent among geriatric inpatients with depression and to determine whether this augmentation was associated with decreased days of clinically needed hospitalization

Methods: A retrospective chart review was conducted of the medical records of patients > 60 years of age discharged from a geriatric psychiatry unit between June 1, 2014, and February 1, 2016. Two groups were compared: those with depression who received folinic acid (leucovorin) supplementation (n = 35) and those with depression who did not receive leucovorin (n = 80). The primary outcome measure was number of clinically needed days of hospitalization.

Results: The mean ± SD number of days (logged) of clinically needed hospitalization in the leucovorin group was 2.0 ± 0.7 compared with 2.4 ± 0.6 in the nonintervention group. Unpaired t group analysis yielded the following: t₁₁₅ = 3.47, P < .0001 (2-tailed).

Conclusions: The patients who received leucovorin had a significantly reduced requirement of days of hospitalization, which translates to reduced cumulative cost of treatment during hospitalization. Further studies, including randomized controlled trials, are recommended to explore this treatment option.

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (36)

Steinman LE, Frederick JT, Prohaska T, et alLate Life Depression Special Interest Project (SIP) Panelists. Recommendations for treating depression in community-based older adults. Am J Prev Med. 2007;33(3):175–181. PubMed CrossRef
Licht-Strunk E, van der Windt DA, van Marwijk HW, et al. The prognosis of depression in older patients in general practice and the community. s systematic review. Fam Pract. 2007;24(2):168–180. PubMed CrossRef
Knöchel C, Alves G, Friedrichs B, et al. Treatment-resistant late-life depression: challenges and perspectives. Curr Neuropharmacol. 2015;13(5):577–591. PubMed CrossRef
Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(suppl):39–47, discussion 48–50. PubMed
Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457–494, x. PubMed CrossRef
Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008;13(3):216–226. PubMed
Shorvon SD, Carney MWP, Chanarin I, et al. The neuropsychiatry of megaloblastic anaemia. BMJ. 1980;281(6247):1036–1038. PubMed CrossRef
Reynolds EH, Preece JM, Bailey J, et al. Folate deficiency in depressive illness. Br J Psychiatry. 1970;117(538):287–292. PubMed CrossRef
Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? a meta-analysis and exploration of heterogeneity. J Epidemiol Community Health. 2007;61(7):631–637. PubMed CrossRef
Kim JM, Stewart R, Kim SW, et al. Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression. Br J Psychiatry. 2008;192(4):268–274. PubMed CrossRef
Dimopoulos N, Piperi C, Salonicioti A, et al. Correlation of folate, vitamin B12 and homocysteine plasma levels with depression in an elderly Greek population. Clin Biochem. 2007;40(9-10):604–608. PubMed CrossRef
Sachdev PS, Parslow RA, Lux O, et al. Relationship of homocysteine, folic acid and vitamin B12 with depression in a middle-aged community sample. Psychol Med. 2005;35(4):529–538. PubMed CrossRef
Bottiglieri T, Reynolds EH, Laundy M. Folate in CSF and age. J Neurol Neurosurg Psychiatry. 2000;69(4):562. PubMed CrossRef
Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. Aging Ment Health. 2016;20(9):965–973. PubMed CrossRef
Bottiglieri T, Hyland K, Laundy M, et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med. 1992;22(4):871–876. PubMed CrossRef
Placidi GP, Oquendo MA, Malone KM, et al. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry. 2001;50(10):783–791. PubMed CrossRef
Goodwin FK, Post RM. 5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology. Br J Clin Pharmacol. 1983;15(suppl 3):393S–405S. PubMed CrossRef
Kaufman S. Some metabolic relationships between biopterin and folate: implications for the “methyl trap hypothesis”. Neurochem Res. 1991;16(9):1031–1036. PubMed CrossRef
Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. Cochrane Databases Syst Rev. 2003;2003(2):CD003390. PubMed CrossRef
Wesson VA, Levitt AJ, Joffe RT. Change in folate status with antidepressant treatment. Psychiatry Res. 1994;53(3):313–322. PubMed CrossRef
Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309–313. PubMed CrossRef
Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986;10(1):9–13. PubMed CrossRef
Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121–130. PubMed CrossRef
Food and Drug Administration. Authors food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Final Rule. 21 CFR Parts 136, 137, and 139. Fed Regist. 1996;61:8781–8789.
Guaraldi GP, Fava M, Mazzi F, et al. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5(2):101–105. PubMed CrossRef
Di Palma C, Urani R, Argicola R, et al. Is methylfolate effective in relieving major depression in chronic alcoholics? a hypothesis of treatment. Curr Ther Res. 1994;55(5):559–568. CrossRef
Ginsberg LD, Oubre AY, Daoud YA. L-methylfolate Plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode. Innov Clin Neurosci. 2011;8(1):19–28. PubMed
Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267–1274. PubMed CrossRef
Shelton RC, Sloan Manning J, Barrentine LW, et al. Assessing effects of L-methyfolate in depression management: results of a real-world patient experience trial. Prim Care Companion CNS Disord. 2013;15(4):PCC.13m01520. PubMed CrossRef
Passeri M, Cucinotta D, Abate G, et al. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993;5(1):63–71. PubMed CrossRef
Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392–395. PubMed CrossRef
Alpert JE, Mischoulon D, Rubenstein GE, et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002;14(1):33–38. PubMed CrossRef
Heslin KC, Elixhauser A, Steiner CA. Hospitalizations involving mental and substance use disorders among adults, 2012: Statistical Brief #191. In: Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Research and Quality; June 2015.
Bell IR, Edman JS, Marby DW, et al. Vitamin B12 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin nondeficient population. Biol Psychiatry. 1990;27(2):125–137. PubMed CrossRef
Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983-1983;17(1):37–49. PubMed CrossRef
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef